DPHA — Disruptive Pharma AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK21.98m
- -SEK12.12m
Brief: A1m Pharma Reports Positive Results From Preclinical Study In Acute Kidney Injuries
Brief: A1M Pharma Q1 Operating Loss Slightly Narrows To SEK 14.6 Million
Brief: A1M Pharma Raises About SEK 62.2 Million In Rights Issue
Brief: A1m Pharma Q4 Pre-tax Loss Narrows To SEK 15.0 Million
Brief: A1M Pharma Gets Patent In Australia
Brief: A1M Pharma Proposes Rights Issue Of About SEK 83 Million
Brief: A1M Pharma Applies For Clinical Phase I Study
Brief: A1M Pharma Enters Into Collaboration With Antaros Medical
Brief: A1M Pharma Gets SEK 3.25 Mln In Warrants Issue
Brief: A1M Pharma Q3 operating loss widens to SEK 18.3 mln
Brief: A1M Pharma able to finalize application to initiate clinical studies
Brief: A1M Pharma files patent application
Brief: A1M Pharma signs agreement with Swedish CRO partner
Brief: A1M Pharma starts trading on Nasdaq First North on June 20
Brief: A1M Pharma says rights issue subscribed at 65.1 pct
Brief: A1M Pharma: ROSGard shows strong protective effect against renal damage in connection with radiation therapy in preclinical long-term study
Brief: A1M Pharma: Mitochondrial protective effect of rA1M in preclinical studies
Brief: A1M: ROSGard shows renal protective effect during radiation therapy
Brief: A1M Pharma successfully conducts preclinical toxicology/safety studies within preeclampsia